Oragenics Regains NYSE Compliance Following $16.5 Million Funding Round for Concussion Treatment Development
Oragenics Inc. has regained full compliance with NYSE American listing standards following a successful $16.5 million public offering, securing financial stability to advance its intranasal concussion treatment through critical clinical trials.
Oragenics Inc. (NYSE American: OGEN) has successfully regained full compliance with NYSE American's continued listing standards, marking a significant financial and regulatory milestone for the clinical-stage biotechnology company. The exchange confirmed compliance with Section 1003(a)(iii) effective October 20, 2025, removing the below-compliance indicator and restoring the company to the roster of compliant issuers. This achievement follows the July 2, 2025, closing of a $16.5 million public offering of Series H Convertible Preferred Stock, which restored stockholder equity and provides critical funding for advancing the company's lead candidate through key clinical development phases.
The regulatory compliance restoration represents more than just meeting exchange requirements—it signals the company's strengthened financial position and commitment to advancing neurological therapeutics. CEO Janet Huffman emphasized that "regaining compliance represents more than a regulatory milestone—it reflects our commitment to transparency, financial discipline, and restoring investor confidence." The successful funding round and subsequent compliance achievement demonstrate the company's ability to navigate financial challenges while maintaining focus on its core therapeutic development objectives.
The $16.5 million in funding will primarily support the advancement of ONP-002, Oragenics' lead candidate being developed as a potential treatment for concussion. The capital will fund key Phase II milestones in Australia and upcoming Phase IIb trials in the United States. ONP-002 represents a novel approach to neurological care, utilizing the company's proprietary intranasal delivery technology designed to enable targeted, non-invasive therapeutics for brain-related conditions. The company aims to develop ONP-002 as the first FDA-approved treatment for concussion, addressing a significant unmet medical need in neurological trauma care.
Oragenics' platform technology extends beyond concussion treatment, with potential applications for neurodegenerative diseases, CNS disorders, and other neurological conditions. The intranasal delivery system represents a promising approach to bypassing the blood-brain barrier, potentially enabling more effective treatment of brain-related conditions. The company's broader vision involves creating what they describe as "a movement around brain-first recovery that transforms how patients, clinicians, and healthcare systems approach neurological trauma." Additional information about the company's developments is available in their newsroom at https://ibn.fm/OGEN.
The combination of regained NYSE compliance and strengthened financial resources positions Oragenics to accelerate its clinical development timeline while maintaining regulatory standing. This dual achievement provides the company with increased credibility among investors and potential partners as it advances through critical clinical trial phases. The successful navigation of both financial and regulatory challenges demonstrates the company's resilience and strategic positioning within the competitive biotechnology landscape, particularly in the specialized field of neurological therapeutics and intranasal drug delivery systems.